Baroreceptor-mediated reflex control of cardiac sympathetic activity does not appear fully until the third week of postnatal age in the rat, possibly because central processing of baroreceptor sensory input is deficient in the neonate. Hyperthyroidism, which accelerates synaptogenesis in the peripheral sympathetic and central nervous systems, was produced by administering 3,3'',5-triiodothyronine (T3) daily, and effects on development of baroreceptor-mediated sympathetic reflexes were evaluated. To test baroreceptor-mediated reflexes, control and T3-treated rats of different ages were given hydralazine acutely to produce a decrease in blood pressure, which in adult rats results in a large, sympathetically-mediated stimulation of cardiac ornithine decarboxylase (ODC) activity. In control neonates, cardiac ODC responses to hydralazine were absent until the 3rd week of age, but the T3-treated animals showed increases as early as 8 days of age. Furthermore, increased turnover of norepinephrine in cardiac sympathetic nerves in response to the hydralazine-induced hypotension was 2- to 3-fold higher in the 8-day-old T3-treated animals than in controls. These data indicate that the early appearance of the ODC response to hypotension in hyperthyroid rats results, at least in part, from precocious development of the ability of baroreceptor input to influence efferent sympathetic function.

Keywords:
Baroreceptor reflexes, Hyperthyroidism, Hydralazine, Sympathetic nerve development, Ornithine decarboxylase
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.